Találati lista | Tudóstér

001-es BibID:	BIBFORM108875
035-os BibID:	(cikkazonosító)4115
Első szerző:	Lőrincz Hajnalka (biológus)
Cím:	Impaired Organokine Regulation in Non-Diabetic Obese Subjects : halfway to the Cardiometabolic Danger Zone / Hajnalka Lőrincz, Balázs Ratku, Sára Csiha, Ildikó Seres, Zoltán Szabó, György Paragh, Mariann Harangi, Sándor Somodi
Dátum:	2023
ISSN:	1422-0067
Megjegyzések:	Altered organokine expression contributes to increased cardiometabolic risk in obesity. Our aim was to evaluate the associations of serum afamin with glucose homeostasis, atherogenic dyslipidemia, and other adipokines in severe obesity to clarify the early metabolic alterations. 106 non diabetic obese (NDO) subjects and 62 obese patients with type 2 diabetes matched for age, gender, and body mass index (BMI) were enrolled in this study. We compared their data with 49 healthy, lean controls. Serum afamin and retinol-binding protein 4 (RBP4), as well as plasma plasminogen activator inhibitor-1 (PAI-1), were measured with ELISA, and lipoprotein subfractions were analyzed using Lipoprint gel electrophoresis. Afamin and PAI-1 found to be significantly higher in the NDO and T2M group (p < 0.001 and p < 0.001, respectively) than in the controls. In contrast, RBP4 was unexpectedly lower in the NDO and T2DM group compared to controls (p < 0.001). Afamin showed negative correlations with mean LDL size and RBP4, but positive correlations with anthropometric, glucose/lipid parameters, and PAI-1 in both the overall patients and the in NDO + T2DM groups. BMI, glucose, intermediate HDL, and small HDL were predictors of afamin. Afamin may serve as a biomarker for the severity of cardiometabolic disturbances in obesity. The complexity of organokine patterns in NDO subjects draws attention to the diverse spectrum of obesity-related comorbidities.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk obesity type 2 diabetes insulin resistance afamin plasminogen-activator inhibitor-1 retinol binding protein 4 lipid metabolism lipoprotein subfraction cardiometabolic
Megjelenés:	International Journal Of Molecular Sciences. - 24 : 4 (2023), p. 1-13. -
További szerzők:	Ratku Balázs (1985-) (mentőtiszt) Csiha Sára (1985-) (Biológus) Seres Ildikó (1954-) (biokémikus) Szabó Zoltán (1973-) (belgyógyász, kardiológus) Paragh György (1953-) (belgyógyász) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Somodi Sándor (1977-) (belgyógyász)
Pályázati támogatás:	PD124126 OTKA K142273 OTKA
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM103904
Első szerző:	Lőrincz Hajnalka (biológus)
Cím:	Plasminogen activator inhibitor-1 level associated with the components of metabolic syndrome in a 4G/5G polymorphism dependent manner / Lőrincz H., Galgóczy E., Katkó M., Ratku B., Ötvös T., Harangi M., Paragh G., Szabó Z., Somodi S.
Dátum:	2022
ISSN:	0021-9150
Megjegyzések:	Background and Aims : The elevated level of plasminogen activator inhibitor- 1 (PAI-1) in obese subjects with metabolic syndrome and in patients with type 2 diabetes is well established. A common 4G/5G single guanine insertion/deletion polymorphism in the promoter region of the PAI-1 gene is of functional importance in regulating PAI-1 expression. We aimed to study the potential different correlations of carbohydrate and lipid parameters and plasma PAI-1 levels in the 4G and 5G carriers in obese and lean subjects. Methods: Ninety-three morbid obese and thirty-two lean non-diabetic participants were enrolled. PAI-1 4G/5G polymorphism was determined with allele-specific PCR. Plasma PAI-1 levels were measured by ELISA. Results: The genotype distribution of PAI-1 4G/5G polymorphism was not significantly differed in obese patients (4G/4G 27.9%; 4G/5G 45.2% and 5G/ 5G 26.9%) compared to controls (4G/4G 31.3%; 4G/5G 46.9% and 5G/5G 21.9%, p?0.8). Slightly higher PAI-1 levels were found in 4G carriers (4G/ 4G+4G/5G) in obese and control group (p?0.07 and p?0.02, respectively). In all subjects with 4G/5G genotype, plasma PAI-1 correlated negatively with high-density lipoprotein-cholesterol (HDL-C) (p?0.02) and apolipoprotein AI (apoAI) levels (p<0.001). In 5G/5G participants, PAI-1 also correlated negatively with HDL-C (p?0.025) and apoAI (p?0.007) concentrations, moreover positively with triglyceride (p?0.02), fasting glucose (p?0.002) and haemoglobin A1c (p?0.027). These correlations are lacking in 4G/4G participants. Conclusions: The observed correlations between PAI-1 levels and the components of metabolic syndrome suggest a closer link between PAI-1 and lipid and carbohydrate metabolism in subjects with 5G/5G genotype. This presentation was supported by the Bridging Fund (Faculty of Medicine, University of Debrecen) and PD124126 project.
Tárgyszavak:	Orvostudományok Egészségtudományok idézhető absztrakt folyóiratcikk atherosclerosis Plasminogen activator inhibitor-1 promoter polymorphism obesity lipid metabolism lipoprotein
Megjelenés:	Atherosclerosis. - 355 (2022), p. e248. -
További szerzők:	Galgóczi Erika (1986-) (biológus) Katkó Mónika (1980-) (biológus) Ratku Balázs (1985-) (mentőtiszt) Ötvös Tamás (1980-) (orvos) Harangi Mariann (1974-) (belgyógyász, endokrinológus) Paragh György (1953-) (belgyógyász) Szabó Zoltán (1973-) (belgyógyász, kardiológus) Somodi Sándor (1977-) (belgyógyász)
Pályázati támogatás:	PD124126 Egyéb
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM100130
Első szerző:	Ratku Balázs (mentőtiszt)
Cím:	Effects of adult growth hormone deficiency and replacement therapy on the cardiometabolic risk profile / Balázs Ratku, Veronika Sebestyén, Annamária Erdei, Endre V. Nagy, Zoltán Szabó, Sándor Somodi
Dátum:	2022
ISSN:	1386-341X 1573-7403
Megjegyzések:	Adult growth hormone deficiency (AGHD) is considered a rare endocrine disorder involving patients with childhood-onset and adult-onset growth hormone deficiency (AoGHD) and characterized by adverse cardiometabolic risk profile. Besides traditional cardiovascular risk factors, endothelial dysfunction, low-grade inflammation, impaired adipokine profile, oxidative stress and hypovitaminosis D may also contribute to the development of premature atherosclerosis and higher cardiovascular risk in patients with AGHD. Growth hormone replacement has been proved to exert beneficial effects on several cardiovascular risk factors, but it is also apparent that hormone substitution in itself does not eliminate all cardiometabolic abnormalities associated with the disease. Novel biomarkers and diagnostic techniques discussed in this review may help to evaluate individual cardiovascular risk and identify patients with adverse cardiometabolic risk profile. In the absence of disease-specific guidelines detailing how to assess the cardiovascular status of these patients, we generally recommend close follow-up of the cardiovascular status as well as low threshold for a more detailed evaluation.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Growth hormone deficiency Cardiometabolic risk Growth hormone replacement therapy Premature atherosclerosis
Megjelenés:	Pituitary. - 25 : 2 (2022), p. 211-228. -
További szerzők:	Borbásné Sebestyén Veronika (1990-) (biofizikus) Erdei Annamária (1976-) (belgyógyász) Nagy Endre V. (1957-) (belgyógyász, endokrinológus) Szabó Zoltán (1973-) (belgyógyász, kardiológus) Somodi Sándor (1977-) (belgyógyász)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM095124
035-os BibID:	(cikkazonosító)614493
Első szerző:	Ujvárosy Dóra
Cím:	Cardiopulmonary Resuscitation With Mechanical Chest Compression Device During Percutaneous Coronary Intervention : a case report / Dóra Ujvárosy, Veronika Sebestyén, Tamás Ötvös, Balázs Ratku, István Lorincz, Tibor Szuk, Zoltán Csanádi, Ervin Berényi, Zoltán Szabó
Dátum:	2021
ISSN:	2297-055X
Megjegyzések:	Sudden cardiac death is a leading cause of death worldwide, whereby myocardial infarction is considered the most frequent underlying condition. Percutaneous coronary intervention (PCI) is an important component of post-resuscitation care, while uninterrupted high-quality chest compressions are key determinants in cardiopulmonary resuscitation (CPR). In our paper, we evaluate a case of a female patient who suffered aborted cardiac arrest due to myocardial infarction. The ambulance crew providing prehospital care for sudden cardiac arrest used a mechanical chest compression device during advanced CPR, which enabled them to deliver ongoing resuscitation during transfer to the PCI laboratory located 20 km away from the scene. Mechanical chest compressions were continued during the primary coronary intervention. The resuscitation, carried out for 2 h and 35 min, and the coronary intervention were successful, as evidenced by the return of spontaneous circulation and by the fact that, after a short rehabilitation, the patient was discharged home with a favorable neurological outcome. Our case can serve as an example for the effective and safe use of a mechanical compression device during primary coronary intervention.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk sudden cardiac death cardiopulmonary resuscitation coronary intervention mechanical chest compression device
Megjelenés:	Frontiers in Cardiovascular Medicine. - 8 (2021), p. 1-6. -
További szerzők:	Borbásné Sebestyén Veronika (1990-) (biofizikus) Ötvös Tamás (1980-) (orvos) Ratku Balázs (1985-) (mentőtiszt) Lőrincz István (1950-) (belgyógyász, kardiológus) Szűk Tibor (1967-) (kardiológus) Csanádi Zoltán (1960-) (kardiológus) Berényi Ervin (1964-) (radiológus) Szabó Zoltán (1973-) (belgyógyász, kardiológus)
Pályázati támogatás:	GINOP-2.3.2-15-2016-00005 GINOP
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: